Overview

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Status:
Active, not recruiting

Trial end date:
2029-02-02

Target enrollment:

Participant gender:

Summary

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Navitoclax